Skandinaviska Enskilda Banken AB publ Sells 32,500 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Skandinaviska Enskilda Banken AB publ lowered its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 77.4% in the 4th quarter, Holdings Channel reports. The firm owned 9,500 shares of the medical equipment provider’s stock after selling 32,500 shares during the quarter. Skandinaviska Enskilda Banken AB publ’s holdings in Lantheus were worth $847,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in LNTH. State of New Jersey Common Pension Fund D lifted its holdings in shares of Lantheus by 0.4% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 26,428 shares of the medical equipment provider’s stock worth $2,364,000 after buying an additional 115 shares in the last quarter. Bleakley Financial Group LLC boosted its holdings in Lantheus by 6.1% in the 4th quarter. Bleakley Financial Group LLC now owns 2,237 shares of the medical equipment provider’s stock valued at $200,000 after purchasing an additional 129 shares during the period. Avantax Advisory Services Inc. grew its position in shares of Lantheus by 5.9% during the 4th quarter. Avantax Advisory Services Inc. now owns 2,382 shares of the medical equipment provider’s stock valued at $213,000 after purchasing an additional 132 shares in the last quarter. UMB Bank n.a. grew its position in shares of Lantheus by 31.5% during the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock valued at $50,000 after purchasing an additional 134 shares in the last quarter. Finally, Arizona State Retirement System increased its holdings in shares of Lantheus by 0.9% in the fourth quarter. Arizona State Retirement System now owns 20,137 shares of the medical equipment provider’s stock worth $1,801,000 after purchasing an additional 178 shares during the period. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Trading Up 1.6 %

Shares of NASDAQ:LNTH opened at $102.76 on Tuesday. The stock has a market capitalization of $7.04 billion, a P/E ratio of 17.10 and a beta of 0.38. The stock’s 50-day moving average price is $92.25 and its 200-day moving average price is $96.67. Lantheus Holdings, Inc. has a 12-month low of $56.44 and a 12-month high of $126.89.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The company had revenue of $391.11 million for the quarter, compared to the consensus estimate of $376.61 million. As a group, research analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Analyst Upgrades and Downgrades

LNTH has been the subject of several recent analyst reports. The Goldman Sachs Group began coverage on Lantheus in a research report on Wednesday, December 18th. They set a “buy” rating and a $143.00 target price for the company. Truist Financial upped their price objective on shares of Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a research report on Thursday, February 27th. JMP Securities reiterated a “market outperform” rating and set a $112.00 target price on shares of Lantheus in a research report on Tuesday, January 14th. Finally, StockNews.com lowered shares of Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $132.86.

Insider Activity at Lantheus

In related news, Director James H. Thrall sold 1,000 shares of the business’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the transaction, the director now owns 33,207 shares in the company, valued at $3,146,695.32. The trade was a 2.92 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Mary Anne Heino sold 53,107 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the sale, the director now owns 440,399 shares of the company’s stock, valued at approximately $41,551,645.65. This trade represents a 10.76 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 54,109 shares of company stock worth $5,105,606 in the last three months. 1.50% of the stock is owned by insiders.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.